The AASLD Clinical Symposium HCV Treatment: Gastroenterologists Role in Eradicating HCV featured a panel of experts who discussed strategies to maximize the number of individuals who are treated for chronic HCV. “Despite recommendations and, in some states, mandates, we are falling behind on HCV screening,” said Robert S. Brown Jr., MD, MPH, AGAF.
Kathleen E. Corey, MD, MPH, MMSc, will deliver “Challenges in Screening for NAFLD (Including At-Risk Populations)” during Clinical Challenges in Adult and Pediatric Non-Alcoholic Fatty Liver Disease on Monday.
Patrick S. Kamath, MD, DM, MBBS, will define acute-on-chronic liver failure and review its history and scope during Monday’s AASLD State-of-the-Art Lecture Acute on Chronic Liver Failure: Pathophysiology and Therapeutic Approach.
Although antiviral therapy has led to a cure rate of more than 90 percent of hepatitis C virus (HCV) cases, David E. Bernstein, MD, FAASLD, thinks more can be done to increase the cure rate. In this DDW Daily News video exclusive, Dr. Bernstein discusses several obstacles preventing patients’ access to curative therapies. He also addresses the benefits of HCV therapy and whether it’s possible to eradicate HCV and achieve 100 percent cure rate.
During Sunday’s AASLD State-of-the-Art Lecture Evolving Management of Cholestatic Liver Diseases, Cynthia Levy, MD, FAASLD, will discuss the treatment of primary biliary cholangitis and primary sclerosing cholangitis, the two most common causes of chronic cholestatic liver disease in adults.
AASLD will feature the most innovative research in its two plenary sessions at DDW®, according to AASLD President Ronald J. Sokol, MD, FAASLD. The Basic Science Plenary Session will be held Sunday morning and the Clinical Science Plenary Session will be held Monday morning. Each will offer something for all AASLD members and DDW attendees.
AASLD’s educational programming at DDW® is designed to provide a broad education on hot liver disease topics for general gastroenterologists, and deeper learning for hepatologists seeking information on the latest research and treatment advances, according to AASLD Secretary Kimberly A. Brown, MD, FAASLD.
The editors of AASLD’s flagships journals, HEPATOLOGY and Liver Transplantation, have organized a comprehensive update on important advances in chronic liver disease for this year’s Hepatology Update: The Year in Review. David Cohen, MD, PhD, FAASLD, editor in chief of HEPATOLOGY, and Paul Martin, MD, FAASLD, editor in chief of Liver Transplantation, will moderate.
An AASLD symposium on the final day of DDW® 2017 brought together experts from around the world to discuss pharmacological therapies, endoscopic therapies, interventional procedures
Alcoholic liver disease (ALD) is one of the leading causes of morbidity and mortality in the U.S. and worldwide. Three hepatologists discussed the management of
